BMS-690514 manufacturers
- BMS-690514
-
- $149.00 / 2mg
-
2026-03-13
- CAS:859853-30-8
- Min. Order:
- Purity: 99.08%
- Supply Ability: 10g
- BMS-690514
-
- $1.00 / 1KG
-
2020-01-01
- CAS:859853-30-8
- Min. Order: 1KG
- Purity: 95-99%
- Supply Ability: 1ton
|
| | BMS-690514 Basic information |
| Product Name: | BMS-690514 | | Synonyms: | BMS-690514;(3R,4R)-4-Amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol;BMS-6690514;(3R,4R)-4-amino-1-[[4-(3-methoxyanilino)pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol;(3R,4R)-4-Amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo-[2,1-f][1,2,4]triazin-5-yl]methyl]piperi;3-Piperidinol, 4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]-, (3R,4R)-;(3R,4R)-4-Amino-1-[[4-[(3...;BMS-690514(BMS-6690514) | | CAS: | 859853-30-8 | | MF: | C19H24N6O2 | | MW: | 368.43 | | EINECS: | 200-528-9 | | Product Categories: | | | Mol File: | 859853-30-8.mol |  |
| | BMS-690514 Chemical Properties |
| density | 1.41 | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Powder | | pka | 14.41±0.40(Predicted) | | color | White to off-white |
| | BMS-690514 Usage And Synthesis |
| Uses | BMS-690514 is a potent and orally active inhibitor of EGFR and VEGFR; has IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively. | | in vivo | BMS-690514 has been shown to be efficacious in a broad spectrum of tumor xenografts. At doses that are efficacious and well tolerated in the animal models, BMS-690514 inhibits tumor cell proliferation and tumor blood flow[1]. The oral bioavailability of BMS-690514 is 78% in mice, 100% in rats, 8% in monkeys, and 29% in dogs. BMS-690514 is able to cross the blood–brain barrier with a brain-to-plasma ratio of 1. The preclinical ADME properties of BMS-690514 suggest good oral bioavailability in humans and metabolism by multiple pathways including oxidation and glucuronidation[2]. | | IC 50 | EGFR: 5 nM (IC50); HER2: 20 nM (IC50); HER4: 60 nM (IC50); VEGFR1; VEGFR2; VEGFR3 | | References | [1] Wong TW, et al. Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families. Clin Cancer Res. 2011 Jun 15;17(12):4031-41. DOI:10.1158/1078-0432.CCR-10-3417
[2] Marathe P, et al. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93. DOI:10.1002/jps.22099 |
| | BMS-690514 Preparation Products And Raw materials |
|